ArticlePCN reports : psychiatry and clinical neurosciences2026
Theta burst stimulation for depressive symptoms in early-stage dementia with Lewy bodies: Protocol for a single-arm open-label feasibility study (DL-TBS Study).
Article in PCN reports : psychiatry and clinical neurosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Depressive symptoms are highly prevalent in early-stage dementia with Lewy bodies (DLB) and are associated with impaired quality of life, functional decline, and increased caregiver burden. However, effective and well-tolerated treatment options for depression in this population remain limited because of marked drug sensitivity and autonomic dysfunction. Theta burst stimulation (TBS), a brief form of repetitive transcranial magnetic stimulation, may represent a promising non-pharmacological intervention; however, its feasibility and safety in patients with DLB have not been systematically investigated. Methods: This single-center, single-arm, open-label feasibility study will be conducted over four weeks. Participants with prodromal and mild DLB and clinically relevant depressive symptoms will receive intermittent TBS targeting the left dorsolateral prefrontal cortex three times per week for four weeks (12 sessions in total). The primary outcome is the completion rate of the 12-session TBS protocol. Secondary outcomes include safety and changes in depressive symptoms, neuropsychiatric symptoms, sleep quality, global clinical severity, cognitive function, cognitive fluctuations, extrapyramidal motor symptoms, activities of daily living, and caregiver burden. Results: This study will evaluate the feasibility and tolerability of TBS in patients with prodromal and mild DLB and will provide descriptive data on changes in clinical outcomes following the intervention. Conclusions: This study will generate critical pilot data regarding the safety and practicality of TBS for depressive symptoms in early-stage DLB. The findings will inform the design of future multicenter, randomized, sham-controlled trials aimed at establishing evidence-based non-pharmacological treatment strategies for this population with limited therapeutic options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.